Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial

Circulation

Volumn 117, Issue 12, 2008, Pages 1518-1525

  Roy, Denis ^a   Pratt, Craig M ^b   Torp Pedersen, Christian ^c   Wyse, D George ^d   Toft, Egon ^e,f   Juul Moller, Steen ^g   Nielsen, Tonny ^h   Rasmussen, S Lind ⁱ   Stiell, Ian G ^j   Coutu, Benoit ^k   Ip, John H ^l   Pritchett, Edward L C ^m   Camm, A John ⁿ  

^a MONTREAL HEART INSTITUTE   (Canada)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^e AALBORG UNIVERSITY   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h Esbjerg Varde Hospital   (Denmark)

ⁱ HVIDOVRE HOSPITAL   (Denmark)

^j UNIVERSITY OF OTTAWA   (Canada)

^k NOTRE DAME HOSPITAL   (Canada)

^l Thoracic and Cardiovascular Institute   (United States)

^m DUKE UNIVERSITY   (United States)

ⁿ ST GEORGE S HOSPITAL   (United Kingdom)

more..

Author keywords

Antiarrhythmia agents; Arrhythmia; Fibrillation; Vernakalant

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DOFETILIDE; FLECAINIDE; PLACEBO; PROCAINAMIDE; PROPAFENONE; QUINIDINE; VERNAKALANT;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOGENIC SHOCK; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; SINUS RHYTHM; SNEEZING; TREATMENT OUTCOME;

AGED; ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CANADA; DOUBLE-BLIND METHOD; DYSGEUSIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PYRROLIDINES; SCANDINAVIA; SNEEZING; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 41149179489     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.723866     Document Type: Article

References (32)

1. Sharif MN, Wyse DG. Atrial fibrillation: overview of therapeutic trials. Can J Cardiol. 1998;14:1241-1254.
2. Slavik RS, Tisdale JE, Borzak S. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. Prog Cardiovasc Dis. 2001;44:121-152.
3. Nichol G, McAlister F, Pham B, Laupacis A, Shea B, Green M, Tang A, Wells G. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart. 2002;87:535-543.
4. Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS, Tieleman RG, Crijns HJGM. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol. 1999;84(suppl 9A):147R-151R.
5. Kowey PR, Marinchak RA, Rials SJ, Filart RA. Acute treatment of atrial fibrillation. Am J Cardiol. 1998;81(suppl 5A):16C-22C.
6. Nattel S, Opie LH. Controversies in atrial fibrillation. Lancet. 2006;367:262-272.
7. Fedida D, Orth PM, Chen JY, Lin S, Plouvier B, Jung G, Ezrin AM, Beatch GN. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005;16:1227-1238.
8. Beatch GN, Shinagawa K, Johnson BD, Jung G, Plouvier B, Zolotoy A, Ezrin AM, Walker MJA, Nattel S. RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodelled atria. Pacing Clin Electrophysiol. 2002;25:698. Abstract.
9. Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic S, Beatch GN. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol. 2007;50:35-40.
10. Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, Lee J, Vidaillet H, Dickinson G, Grant S, Ezrin AM, Beatch GN, for the CRAFT Investigators. A randomized, controlled trial of RSD1235, a novel antiarrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004;44:2355-2361.
11. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC Jr, Meissner MD, Zoble RG, Wakefield LK, Perry KT, VanderLugt JT, for the Ibutilide Investigators. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and flutter: a dose-response study. J Am Coll Cardiol. 1996;28:130-136.
12. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT, for the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 1996;94:1613-1621.
13. Abi-Mansour P, Carberry PA, McCowan RJ, Henthorn RW, Dunn GH, Perry KT. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Am Heart J. 1998;136:632-642.
14. Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation. 1997;96:4298-4306.
15. Volgman AS, Carberry PA, Stambler B, Lewis WR, Dunn GH, Perry KT, VanderLugt JT, Kowey PR. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 1998;31:1414-1419.
16. Vos MA, Golitsyn SR, Stangl K, Ruda MY, Van Wijk L, Harry JD, Perry KT, Touboul P, Steinbeck G, Wellens HJJ. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. Heart. 1998;79:568-575.
17. Vardas PE, Kochiadakis GE, Igoumendidis NE, Tsatsakis AM, Simantirakis EN, Chlouverakis GI. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest. 2000;117:1538-1545.
18. Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, García-Dorado D, Soler-Soler J. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1996;27:1079-1082.
19. Hersi A, Wyse DG. Management of atrial fibrillation. Curr Probl Cardiol. 2005;30:175-233.
20. Hou Z-Y, Chang M-S, Chen C-Y, Tu M-S, Lin S-L, Chiang H-T, Woosley RL. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: a randomized, digoxin-controlled study. Eur Heart J. 1995;16:521-528.
21. Cotter G, Blatt A, Kaluski E, Metzkor-Cotter E, Koren M, Litinski I, Simantov R, Moshkovitz Y, Zaidenstein R, Peleg E, Vered Z, Golik A. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. Eur Heart J. 1999;20:1833-1842.
22. Bianconi L, Boccadamo R, Pappalardo A, Gentili C, Pistolese M. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol. 1989;64:335-338.
23. Goy JJ, Kaufmann U, Kappenberger L, Sigwart U. Restoration of sinus rhythm with flecainide in patients with atrial fibrillation. Am J Cardiol. 1988;62:38D-40D.
24. Borgeat A, Goy J-J, Maendly R, Kaufmann U, Grbic M, Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol. 1986;58:496-498.
25. Fresco C, Proclemer A, Pavan A, Buia G, Vicentini A, Pavan D, Morgera T, for the Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Clin Cardiol. 1996;19:409-412.
26. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation: Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol. 1997;79:418-423.
27. Suttorp MJ, Kingma JH, Jessurun ER, Lie AH, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol. 1990;16:1722-1727.
28. Madrid AH, Moro C, Marin-Huerta E, Mestre JL, Novo L, Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J. 1993;14:1127-1131.
29. Falk RH, Pollak A, Singh SN, Friedrech T. Intravenous dofetilide, a class III antiarrhythmic agent for the termination of sustained atrial fibrillation or flutter. Intravenous dofetilide investigators. J Am Coll Cardiol. 1997;29:385-390.
30. Bianconi L, Castro A, Dinelli M, Alboni P, Pappalardo A, Richiardi E, Santini M, for the Italian Intravenous Dofetilide Study Group. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter: a multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J. 2000;21:1265-1273.
31. Nørgaard BL, Wachtell K, Christensen PD, Madsen B, Johansen JB, Christiansen EH, Graff O, Simonsen EH, for the Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Am Heart J. 1999;137:1062-1069.
32. Hohnloser SH, Dorian P, Straub M, Beckmann K, Kowey P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J Am Coll Cardiol. 2004;44:99-104.